(CL2) Leveraged MSCI USA Daily - Overview
Etf: Stocks, Leveraged, US, Large-Cap, Daily
| Risk 5d forecast | |
|---|---|
| Volatility | 30.6% |
| Relative Tail Risk | -3.82% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.16 |
| Alpha | -17.46 |
| Character TTM | |
|---|---|
| Beta | 0.442 |
| Beta Downside | 0.911 |
| Drawdowns 3y | |
|---|---|
| Max DD | 42.90% |
| CAGR/Max DD | 0.65 |
Description: CL2 Leveraged MSCI USA Daily January 21, 2026
The Amundi ETF Leveraged MSCI USA Daily UCITS (ticker CL2) is a France-domiciled, leveraged equity ETF that seeks to deliver twice the daily performance of the MSCI USA Index. It falls under the “Trading – Leveraged/Inverse Equity” category, meaning it is designed for short-term tactical exposure rather than long-term buy-and-hold investing.
Key quantitative points (as of the latest data in 2025) include an expense ratio of roughly 0.45 % p.a., a 2× leverage factor applied on a daily reset, and an average tracking error of about 1.2 % vs. the underlying index over a 30-day horizon. The fund’s sector tilt mirrors the MSCI USA composition, with the largest weights in technology (≈ 25 %), consumer discretionary (≈ 15 %), and health care (≈ 13 %). Performance is highly sensitive to US macro drivers such as the Federal Reserve policy stance, corporate earnings growth, and volatility in the S&P 500, which together explain the majority of the fund’s daily return variance.
For a deeper quantitative breakdown, you might explore ValueRay’s analytics platform to assess the fund’s risk-adjusted return profile under different market scenarios.
What is the price of CL2 shares?
Over the past week, the price has changed by -0.25%, over one month by -4.59%, over three months by -6.16% and over the past year by -6.20%.
Is CL2 a buy, sell or hold?
What are the forecasts/targets for the CL2 price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 28.6 | 18.2% |
CL2 Fundamental Data Overview February 03, 2026
Revenue TTM = 0.0 EUR
EBIT TTM = 0.0 EUR
EBITDA TTM = 0.0 EUR
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 988.6m EUR (988.6m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 988.6m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 988.6m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 25.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 7.55% (E(988.6m)/V(988.6m) * Re(7.55%) + (debt-free company))
Discount Rate = 7.55% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Fair Price DCF = unknown (Cash Flow 0.0)